Karyopharm Therapeutics Inc. Selling, General and Administrative Expense
Karyopharm Therapeutics Inc. (KPTI) reported Selling, General and Administrative Expense of $25.92 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-13
- Karyopharm Therapeutics Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $25.92M, a 8.99% decline year-over-year.
- Karyopharm Therapeutics Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $26.68M, a 2.44% decline year-over-year.
- Karyopharm Therapeutics Inc. selling, general and administrative expense for the quarter ending 2025-12-31 was $22.77M, a 16.25% decline year-over-year.
- Karyopharm Therapeutics Inc. selling, general and administrative expense for the quarter ending 2025-09-30 was $26.61M, a 3.71% decline year-over-year.
- Karyopharm Therapeutics Inc. selling, general and administrative expense for fiscal 2025 was $105.21M, a 8.86% decline from fiscal 2024.
- Karyopharm Therapeutics Inc. selling, general and administrative expense for fiscal 2024 was $115.44M, a 12.47% decline from fiscal 2023.
- Karyopharm Therapeutics Inc. selling, general and administrative expense for fiscal 2023 was $131.88M, a 9.30% decline from fiscal 2022.
- Karyopharm Therapeutics Inc. selling, general and administrative expense for fiscal 2022 was $145.40M, a 1.08% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $25.92M 10-Q · filed 2026-08-13 | $52.60M 10-Q · filed 2026-08-13 | $75.37M derived: sum of 3 quarters · filed 2026-08-13 | $101.98M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $26.68M 10-Q · filed 2026-05-14 | $49.46M derived: sum of 2 quarters · filed 2026-05-14 | $76.06M derived: sum of 3 quarters · filed 2026-05-14 | $104.54M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $22.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $49.38M derived: sum of 2 quarters · filed 2026-02-13 | $77.86M derived: sum of 3 quarters · filed 2026-08-13 | $105.21M 10-K · filed 2026-02-13 |
| 2025-09-30 | $26.61M 10-Q · filed 2025-11-03 | $55.08M derived: sum of 2 quarters · filed 2026-08-13 | $82.44M 10-Q · filed 2025-11-03 | $109.63M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $28.48M 10-Q · filed 2026-08-13 | $55.83M 10-Q · filed 2026-08-13 | $83.02M derived: sum of 3 quarters · filed 2026-08-13 | $110.65M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $27.35M 10-Q · filed 2026-05-14 | $54.54M derived: sum of 2 quarters · filed 2026-05-14 | $82.17M derived: sum of 3 quarters · filed 2026-05-14 | $113.24M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $27.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $54.82M derived: sum of 2 quarters · filed 2026-02-13 | $85.89M derived: sum of 3 quarters · filed 2026-02-13 | $115.44M 10-K · filed 2026-02-13 |
| 2024-09-30 | $27.63M 10-Q · filed 2025-11-03 | $58.70M derived: sum of 2 quarters · filed 2025-11-03 | $88.25M 10-Q · filed 2025-11-03 | $118.94M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-06-30 | $31.07M 10-Q · filed 2025-08-11 | $60.62M 10-Q · filed 2025-08-11 | $91.31M derived: sum of 3 quarters · filed 2026-02-13 | $122.11M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-03-31 | $29.55M 10-Q · filed 2025-05-12 | $60.24M derived: sum of 2 quarters · filed 2026-02-13 | $91.04M derived: sum of 3 quarters · filed 2026-02-13 | $125.52M derived: sum of 4 quarters · filed 2026-02-13 |
| 2023-12-31 | $30.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $61.49M derived: sum of 2 quarters · filed 2026-02-13 | $95.97M derived: sum of 3 quarters · filed 2026-02-13 | $131.88M 10-K · filed 2026-02-13 |
| 2023-09-30 | $30.80M 10-Q · filed 2024-11-05 | $65.29M derived: sum of 2 quarters · filed 2024-11-05 | $101.19M 10-Q · filed 2024-11-05 | $135.84M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-06-30 | $34.48M 10-Q · filed 2024-08-06 | $70.39M 10-Q · filed 2024-08-06 | $105.04M derived: sum of 3 quarters · filed 2025-02-19 | $139.68M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-03-31 | $35.91M 10-Q · filed 2024-05-08 | $70.56M derived: sum of 2 quarters · filed 2025-02-19 | $105.20M derived: sum of 3 quarters · filed 2025-02-19 | $142.54M derived: sum of 4 quarters · filed 2025-02-19 |
| 2022-12-31 | $34.65M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $69.29M derived: sum of 2 quarters · filed 2025-02-19 | $106.63M derived: sum of 3 quarters · filed 2025-02-19 | $145.40M 10-K · filed 2025-02-19 |
| 2022-09-30 | $34.65M 10-Q · filed 2023-11-02 | $71.98M derived: sum of 2 quarters · filed 2023-11-02 | $110.75M 10-Q · filed 2023-11-02 | $145.31M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $37.34M 10-Q · filed 2023-08-02 | $76.11M 10-Q · filed 2023-08-02 | $110.67M derived: sum of 3 quarters · filed 2024-02-29 | $145.77M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $38.77M 10-Q · filed 2023-05-04 | $73.33M derived: sum of 2 quarters · filed 2024-02-29 | $108.43M derived: sum of 3 quarters · filed 2024-02-29 | $144.96M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $34.56M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $69.67M derived: sum of 2 quarters · filed 2024-02-29 | $106.20M derived: sum of 3 quarters · filed 2024-02-29 | $143.85M 10-K · filed 2024-02-29 |
| 2021-09-30 | $35.10M 10-Q · filed 2022-11-03 | $71.63M derived: sum of 2 quarters · filed 2022-11-03 | $109.28M 10-Q · filed 2022-11-03 | $143.21M derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-06-30 | $36.53M 10-Q · filed 2022-08-04 | $74.18M 10-Q · filed 2022-08-04 | $108.11M derived: sum of 3 quarters · filed 2023-02-17 | $139.08M derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-03-31 | $37.65M 10-Q · filed 2022-05-05 | $71.58M derived: sum of 2 quarters · filed 2023-02-17 | $102.55M derived: sum of 3 quarters · filed 2023-02-17 | $133.39M derived: sum of 4 quarters · filed 2023-02-17 |
| 2020-12-31 | $33.93M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $64.90M derived: sum of 2 quarters · filed 2023-02-17 | $95.74M derived: sum of 3 quarters · filed 2023-02-17 | $126.42M 10-K · filed 2023-02-17 |
| 2020-09-30 | $30.97M 10-Q · filed 2021-11-03 | $61.81M derived: sum of 2 quarters · filed 2021-11-03 | $92.49M 10-Q · filed 2021-11-03 | $120.88M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $30.84M 10-Q · filed 2021-08-05 | $61.52M 10-Q · filed 2021-08-05 | $89.91M derived: sum of 3 quarters · filed 2022-03-01 | $115.18M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $30.68M 10-Q · filed 2021-05-04 | $59.07M derived: sum of 2 quarters · filed 2022-03-01 | $84.33M derived: sum of 3 quarters · filed 2022-03-01 | $109.00M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $28.39M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $53.66M derived: sum of 2 quarters · filed 2022-03-01 | $78.32M derived: sum of 3 quarters · filed 2022-03-01 | $105.42M 10-K · filed 2022-03-01 |
| 2019-09-30 | $25.27M 10-Q · filed 2020-11-02 | $49.93M derived: sum of 2 quarters · filed 2020-11-02 | $77.03M 10-Q · filed 2020-11-02 | $95.80M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $24.66M 10-Q · filed 2020-08-04 | $51.77M 10-Q · filed 2020-08-04 | $70.54M derived: sum of 3 quarters · filed 2021-02-24 | $83.50M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $27.10M 10-Q · filed 2020-05-05 | $45.87M derived: sum of 2 quarters · filed 2021-02-24 | $58.84M derived: sum of 3 quarters · filed 2021-02-24 | |
| 2018-12-31 | $18.77M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $31.74M derived: sum of 2 quarters · filed 2021-02-24 | $48.85M 10-K · filed 2021-02-24 | |
| 2018-09-30 | $12.97M 10-Q · filed 2019-11-04 | $30.08M 10-Q · filed 2019-11-04 | ||
| 2017-12-31 | $24.87M 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |